GGrantIndex
← Leaderboards

Warren Kline Bolton

University Of Virginia Charlottesville

$2,625,219
Attributed
$2,625,219
Total exposure
9
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $604K · FY200511
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11

Funding mix

By agency

NIH$2,625,219 · 9

By mechanism

R01$1,665,819 · 2
M01$547,320 · 6
R21$412,080 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Virginia Charlottesville

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchMorbidity - Disease RateMimeticsEnd Stage Renal FailureKidneyImmuneCytokineHuman SubjectAntigensRenal FunctionDrug Screening /EvaluationPathogenesisHuman Therapy EvaluationGlomerulonephritisResourcesMalnutritionKidney DisorderFuturePathologic ProcessAmino AcidsDouble-Blind MethodDown-RegulationCholinesterase InhibitorsDisease Progression

Grant awards (19)

Experimental Autoimmune Nephritis: Epitope Spreading in Pathogenesis and Control$306,864
R01 · FY2011 · DK · contact PI
Experimental Autoimmune Nephritis: Epitope Spreading in Pathogenesis and Control$310,218
R01 · FY2010 · DK · contact PI
Experimental Autoimmune Nephritis: Epitope Spreading in Pathogenesis and Control$313,602
R01 · FY2009 · DK · contact PI
GROWTH HORMONE SECRETAGOGUE MK-677 THERAPY EFFECT ON IGF-1 LEVELS IN CKD & ESRD$45,821
M01 · FY2009 · RR · contact PI
Experimental Autoimmune Nephritis: Epitope Spreading in Pathogenesis and Control$322,717
R01 · FY2008 · DK · contact PI
Growth hormone secretagogue MK-677 therapy in CKD and ESRD$222,705
R21 · FY2008 · DK · contact PI
GROWTH HORMONE SECRETAGOGUE MK-677 THERAPY EFFECT ON IGF-1 LEVELS IN CKD & ESRD$58,600
M01 · FY2008 · RR · contact PI
Growth hormone secretagogue MK-677 therapy in CKD and ESRD$189,375
R21 · FY2007 · DK · contact PI
ASSESSMENT OF GHRELIN LEVELS IN END STAGE RENAL DISEASE (ESRD)$12,253
M01 · FY2006 · RR · contact PI
ASSESSMENT OF GHRELIN LEVELS IN CHRONIC KIDNEY DISEASE$11,030
M01 · FY2005 · RR
Assessment Of Ghrelin Levels In Chronic Kidney Disease$46,358
M01 · FY2004 · RR
DONEPEZIL HYDROCHLORIDE (ARICEPT) PHARMACOKINETICS$48,533
M01 · FY2002 · RR
NEPHRITOGENIC EPITOPES IN GOODPASTURES SYNDROME$211,285
R01 · FY2001 · DK
DONEPEZIL HYDROCHLORIDE (ARICEPT) PHARMACOKINETICS$48,533
M01 · FY2001 · RR
PLACEBO CONTROLLED SAFETY AND EFFICACY OF AMINOGUANIDINE IN DIABETIC PATIENTS$248,088
M01 · FY2000 · RR
NEPHRITOGENIC EPITOPES IN GOODPASTURES SYNDROME$201,133
R01 · FY2000 · DK
PLACEBO CONTROLLED SAFETY AND EFFICACY OF AMINOGUANIDINE IN DIABETIC PATIENTS$28,104
M01 · FY2000 · RR
DONEPEZIL HYDROCHLORIDE (ARICEPT) PHARMACOKINETICS$0
M01 · FY2000 · RR
DONEPEZIL HYDROCHLORIDE (ARICEPT) PHARMACOKINETICS$0
M01 · FY2000 · RR